Onconova Therapeutics Inc... (ONTX)
NASDAQ: ONTX
· Real-Time Price · USD
1.00
0.00 (0.00%)
At close: Apr 02, 2024, 10:00 PM
Onconova Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2018 |
|---|---|
| Symbio Amortization Of Upfront Payment Revenue | 398K |
| Symbio Amortization Of Upfront Payment Revenue Growth | n/a |
| Hanx Upfront Licence Payment Revenue | 450K |
| Hanx Upfront Licence Payment Revenue Growth | n/a |
| Pint Upfront Licence Payment Revenue | 319K |
| Pint Upfront Licence Payment Revenue Growth | n/a |
| Supplies Revenue | 61K |
| Supplies Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.75B | 12,289B | 3.48M | 1.98B | 3.36M | 2.08M | 2.69M | 2.21M | 2.11M | 2.02M | 2.1M | 2.14M | 2.19M | 2.07M | 2.28M | 2.85M | 2.22M | 1.78M | 2.15M | 2.59M | 1.81M | 1.71M | 1.64M | 1.76M | 3.23M | 1.91M | 1.73M | 2.05M | 1.89M | 1.78M | 1.73M | 1.78M | 2.12M | 1.95M | 1.98M | 2.08M | 3.17M | 1.78M | 2.22M | 2.57M | 2.96M |
| Selling, General, and Administrative Revenue Growth | -99.98% | +353131850.40% | -99.82% | +58809.42% | +61.04% | -22.41% | +21.48% | +4.64% | +4.76% | -4.18% | -1.59% | -2.15% | +5.40% | -9.19% | -19.86% | +28.55% | +24.69% | -17.19% | -17.23% | +43.55% | +5.61% | +4.33% | -6.82% | -45.58% | +68.97% | +10.70% | -15.82% | +8.73% | +6.00% | +3.12% | -2.87% | -15.93% | +8.57% | -1.32% | -5.18% | -34.33% | +77.90% | -19.58% | -13.67% | -13.39% | n/a |
| Research and Development Revenue | 2.51B | 12,847B | 5.11M | 3.96B | 1.91M | 2.43M | 2.46M | 2.46M | 4.08M | 3.77M | 3.59M | 2.04M | 2M | 1.75M | 1.76M | 1.85M | 1.94M | 4.53M | 4.19M | 4.8M | 3.37M | 4.05M | 3.52M | 3.9M | 4.08M | 4.29M | 3.98M | 4.07M | 4.58M | 4.48M | 5.14M | 4.61M | 4.89M | 4.69M | 3.99M | 5.56M | 5.82M | 4.6M | 5.28M | 6.51M | 9.5M |
| Research and Development Revenue Growth | -99.98% | +251261257.21% | -99.87% | +207222.18% | -21.45% | -1.06% | +0.16% | -39.80% | +8.14% | +5.01% | +76.30% | +1.80% | +14.73% | -1.02% | -4.81% | -4.39% | -57.28% | +8.13% | -12.66% | +42.46% | -16.73% | +14.94% | -9.60% | -4.42% | -5.06% | +7.70% | -2.09% | -11.08% | +2.21% | -12.90% | +11.42% | -5.57% | +4.09% | +17.61% | -28.27% | -4.43% | +26.48% | -12.85% | -18.89% | -31.44% | n/a |